Dr. Bin Wang is a distinguished Fudan University School of Basic Medical Sciences professor and the founder and chairman of Advaccine Biotechnology Co LTD. He also serves as the chairman of the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulation. He has developed novel adjuvants, recombinant vaccines, and novel DNA vaccine delivery, which has resulted in several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He was one of the very early inventors of DNA vaccine technology in the 90s and performed the first-in-human DNA vaccine trials in 1994-1996. In recent years, he has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published more than 160 peer-review articles and has been awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and is an executive member of several professional societies.